Population pharmacokinetics of carboplatin in children

被引:47
作者
Chatelut, E
Boddy, AV
Peng, B
Rubie, H
Lavit, M
Dezeuze, A
Pearson, ADJ
Roche, H
Robert, A
Newell, DR
Canal, P
机构
[1] CHR TOULOUSE,TOULOUSE,FRANCE
[2] UNIV NEWCASTLE UPON TYNE,CANC RES UNIT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
关键词
D O I
10.1016/S0009-9236(96)90113-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: In pediatric patients, administration of carboplatin according to body surface area results in a large variation in the area under the plasma ultrafilterable carboplatin concentration versus time curve, A population pharmacokinetic study using the NONMEM program was undertaken to determine the effects of a variety of covariates on the clearance of ultrafilterable carboplatin. Patients: Plasma carboplatin pharmacokinetics were determined in 57 children (2 months to 18 years old, with serum creatinine levels ranging from 27 to 268 mu mol/L) treated for various tumor types. Results: The best fit corresponded to the formula: clearance (ml/min) = 2.85 . weight . (1 - 0.00357 . serum creatinine) . (1 - 0.372 . Np) + 8.7 (with serum creatinine in micromoles per liter, weight in kilograms, and Np = 1 or 0 for unilateral nephrectomy or not, respectively). The interindividual variability in clearance, as expressed by the coefficient of variation, decreased from 74% (no covariates) to 49% by taking account of weight, and to 29% under the final regression formula. Conclusion: The ability of this formula to predict carboplatin clearance in children should be evaluated prospectively and compared to a method based on the determination of the glomerular filtrationrate.
引用
收藏
页码:436 / 443
页数:8
相关论文
共 28 条
[1]  
Beal SL., 1992, NONMEM USERS GUIDE 6
[2]  
BEAL SL, 1985, DRUG FATE METABOLISM, V5, P135
[3]  
BEHRMAN RE, 1983, NELSON TXB PEDIATRIC
[4]   A NOVEL PHARMACODYNAMICALLY BASED APPROACH TO DOSE OPTIMIZATION OF CARBOPLATIN WHEN USED IN COMBINATION WITH ETOPOSIDE [J].
BELANI, CP ;
EGORIN, MJ ;
ABRAMS, JS ;
HIPONIA, D ;
EISENBERGER, M ;
AISNER, J ;
VANECHO, DA .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1896-1902
[5]  
BOECKMANN AJ, 1992, NONMEM USERS GUIDE 5
[6]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[7]  
CHANTLER C, 1969, CLIN SCI, V37, P169
[8]   PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS [J].
CHATELUT, E ;
CANAL, P ;
BRUNNER, V ;
CHEVREAU, C ;
PUJOL, A ;
BONEU, A ;
ROCHE, H ;
HOUIN, G ;
BUGAT, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (08) :573-580
[9]   CLINICAL-TRIAL AND PHARMACOKINETICS OF CARBOPLATIN 560 MG/M2 IN CHILDREN [J].
DOZ, F ;
BRUGIERES, L ;
BASTIAN, G ;
QUINTANA, E ;
LEMERLE, J ;
ZUCKER, JM .
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (06) :459-465
[10]   WHAT IS THE PLACE OF CARBOPLATIN IN PEDIATRIC ONCOLOGY [J].
DOZ, F ;
PINKERTON, R .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (02) :194-201